Cell therapy represents one of the most impactful applications of synthetic biology in medicine. Rather than treating disease with chemical drugs, cell therapies use living cells as the therapeutic agent. The most prominent example is CAR-T cell therapy, where a patient's own T cells (immune cells) are extracted, genetically engineered to express a chimeric antigen receptor (CAR) that targets cancer cells, expanded in the laboratory, and infused back into the patient. The engineered cells then seek out and destroy cancer throughout the body.
The clinical success of CAR-T therapy has been remarkable. Novartis' Kymriah and Gilead's Yescarta, both approved by the FDA in 2017, have achieved complete remissions in patients with previously untreatable blood cancers. Since then, additional CAR-T products have been approved, and the technology is being extended to solid tumors, autoimmune diseases, and other conditions. Companies like Allogene Therapeutics and CRISPR Therapeutics are developing "off-the-shelf" allogeneic cell therapies using donor cells, which could dramatically reduce cost and treatment time.
Synthetic biology is central to next-generation cell therapies. Researchers are building increasingly sophisticated gene circuits into therapeutic cells — logic gates that activate killing only when multiple tumor markers are present, safety switches that allow cells to be deactivated if adverse effects occur, and armor genes that protect engineered cells from the immunosuppressive tumor microenvironment. The intersection of synthetic biology and cell therapy is creating a new class of programmable medicines with capabilities far beyond traditional pharmaceuticals. For deeper coverage, see SynBioIntel.